99mTc Sestamibi SPECT/CT vs 18F Fluorocholine PET/CT
Phase 2
Recruiting
- Conditions
- Parathyroid Adenoma
- Interventions
- Drug: 18Fluorocholine
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 100
- Registration Number
- NCT05891769
- Locations
- 🇺🇸
Stanford Hospital and Clinics, Stanford, California, United States
Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
Phase 2
Not yet recruiting
- Conditions
- Head-and-neck Squamous Cell Carcinoma
- Interventions
- Drug: 89Zr-panitumumab IV
- First Posted Date
- 2022-06-21
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 60
- Registration Number
- NCT05423197
- Locations
- 🇺🇸
Stanford Cancer Institute, San Francisco, California, United States
Study Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
Phase 1
Recruiting
- Conditions
- Head and Neck Cancer
- Interventions
- Procedure: Single photon emission computed tomography/computed tomography (SPECT/CT) scans
- First Posted Date
- 2021-04-12
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 28
- Registration Number
- NCT04840472
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
HDR Brachytherapy 68-Ga-RM2 PET, 68-Ga-PSMA-11 PET &Multi Parametric MRI in Prostate Cancer
Phase 2
Terminated
- Conditions
- Prostate Cancer
- Interventions
- Drug: 68-Ga RM2.Drug: 68-Ga PSMA11Device: PET/MRI
- First Posted Date
- 2020-02-11
- Last Posted Date
- 2024-02-01
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 4
- Registration Number
- NCT04264208
- Locations
- 🇺🇸
Stanford Cancer Center, Stanford, California, United States
68-Ga PSMA 11 PET/MRI and 68-Ga RM2 PET/MRI for Evaluation of Prostate Cancer Response to HIFU Therapy
Phase 1
Completed
- Conditions
- Prostate Cancer
- Interventions
- Drug: 68-Ga RM2Drug: 68-Ga PSMA11Device: Investigational software and coils in PET/MR ScanProcedure: PET/MRI
- First Posted Date
- 2019-05-14
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 14
- Registration Number
- NCT03949517
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
Phase 1
Completed
- Conditions
- Estrogen Receptor PositiveBreast Carcinoma
- Interventions
- Procedure: Magnetic Resonance ImagingProcedure: Positron Emission TomographyDevice: Investigational software and coils in PET/MR scan
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2023-12-13
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 5
- Registration Number
- NCT03831711
- Locations
- 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
18F-FSPG PET/CT in Diagnosing Early Lung Cancer in Patients With Lung Nodules
Phase 2
Completed
- Conditions
- Multiple Pulmonary NodulesPulmonary NoduleCurrent SmokerCigarette SmokerFormer Smoker
- Interventions
- Diagnostic Test: Computed TomographyDiagnostic Test: Positron Emission Tomography (PET/CT)
- First Posted Date
- 2019-01-31
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 15
- Registration Number
- NCT03824535
- Locations
- 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
68Ga PSMA 11 PET/MRI and 68Ga RM2 PET/MRI for Biopsy Guidance in Patients With Suspected Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2019-01-18
- Last Posted Date
- 2024-01-11
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 14
- Registration Number
- NCT03809078
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck Cancer
Phase 1
Completed
- Conditions
- Squamous Cell Carcinoma of the Head and NeckCarcinoma of the Head and Neck
- Interventions
- Drug: 89-Zirconium (Zr-89) PanitumumabDevice: Pinpoint IR IR9000 fluorescence imaging system (FIS)Device: SPY-PHI IR9000 fluorescence imaging system (FIS)Device: Explorer Air cameraDevice: PDE-NEO II cameraDevice: FIS-00 fluorescence imaging system (FIS)Device: Da Vinci Firefly Imaging SystemDevice: IGP-ELVIS-v4 Macroscopic Specimen ImagerDevice: Vevo 3100 LAZR-XDevice: Pearl Triology Imaging SystemDevice: Odyssey CLx Imaging SystemDevice: Leica fluorescence microscope
- First Posted Date
- 2018-11-07
- Last Posted Date
- 2023-05-19
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 14
- Registration Number
- NCT03733210
- Locations
- 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer
Phase 2
Completed
- Conditions
- Recurrent Prostate CarcinomaPSA ProgressionProstate Adenocarcinoma
- Interventions
- Device: Gallium Ga 68 PSMA-R2
- First Posted Date
- 2018-10-09
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Andrei Iagaru
- Target Recruit Count
- 27
- Registration Number
- NCT03698370
- Locations
- 🇺🇸
Stanford Cancer Institute Palo Alto, Palo Alto, California, United States